Fig. 1From: Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18Progression-free survival (intention-to-treat population) in subgroups based on age, histological type of breast cancer, and history of prior neoadjuvant/adjuvant systemic treatment. CI confidence interval, LET letrozoleBack to article page